BLTE

Belite Bio, Inc

$147.34

+3.19% 2026-10-19

Healthcare

1M 3M 6M 1Y 2Y

BLTESPY

-7.1%

-13.8%

-3.6%

-10.9%

YTD

-7.9%

+68.0%

Grades vs sector

Momentum

no data

–

Percentile within its GICS sector across the S&P 1500.

Growth

no data

–

Percentile within its GICS sector across the S&P 1500.

Value

no data

–

Percentile within its GICS sector across the S&P 1500.

Profitability

no data

–

Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap$5.9B

P/E (trailing)–

P/E (forward)65.2

52-week range86.57 – 200.00

Revenue growth (YoY, latest qtr)–

Dividend yield0.00%

Analyst consensusStrong Buy (9)

Mean price target$228.89 (+55%)

Valuation & fundamentals

No US-GAAP 10-K/10-Q financials in SEC data (foreign filers report on Form 20-F, often under IFRS).

Earnings

Next report: 2026-11-09 · during market · EPS est -0.77

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-13	-0.78	-0.70	+9.9%
2026-05-20	-0.64	-0.68	-5.8%
2026-03-02	-0.54	-0.70	-30.3%
2025-11-10	-0.49	-0.65	-32.6%
2025-08-11	-0.42	-0.50	-19.8%
2025-05-14	-0.36	-0.45	-23.3%
2025-03-17	-0.31	-0.32	-4.1%
2024-11-12	-0.30	-0.28	+6.7%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$0	–
2026-03-31	$0	–
2025-12-31	$0	–
2025-09-30	$0	–
2025-06-30	$0	–

Analyst actions

HC Wainwright & Co.

2026-10-15 · reit

Buy → Buy
PT $245

Mizuho

2026-09-09 · main

Outperform → Outperform
PT $234

HC Wainwright & Co.

2026-09-08 · main

Buy → Buy
PT $245

Canaccord Genuity

2026-09-04 · init

→ Buy
PT $303

Morgan Stanley

2026-08-14 · main

Overweight → Overweight
PT $206

Cantor Fitzgerald

2026-08-14 · main

Overweight → Overweight
PT $270